Rhabdomyosarcoma Therapeutics Analysis 2018 - Clinical Trials, Designations, Collaborations and Developments

According to the research findings, most of the drug candidates for the treatment of RMS are being developed to be administered by the intravenous route. The main advantage associated with the intravenous route is that the drug can easily be entered into the bloodstream, or lymph vessels, resulting in high bioavailability of the drug in the body and quick onset of action of drug.

Explore report sample at: https://www.psmarketresearch.com/market-analysis/rms-therapeutics-pipeline-analysis/report-sample

Several companies are developing combination therapies for the treatment of RMS, as these therapies are cost-effective and improve medication compliance by reducing burden of pills. For instance, (Dasatinib + Ganitumab) is a combination therapy under the Phase II stage of development by Bristol-Myers Squibb Company for the treatment of RMS. The drug candidate is a combination of small molecule (dasatinib) and monoclonal antibody (ganitumab), obtained from synthetic and natural source, respectively. It acts as Bcr-abl tyrosine kinase inhibitor and EphA2 receptor antagonist (dasatinib); and insulin-like growth factor-I receptor antagonist (ganitumab).

Most of the companies are developing drug candidates using advanced technologies, and these drug candidates have showed positive efficacy in the clinical stage of development. For instance, Iproteos SL is developing its drug candidate using IPROTech technology platform which involves a combination of in-silico and in-vitro techniques. The technology encompasses state-of-the-art of various scientific fields, such as computational chemistry, modern organic synthesis, peptide chemistry, and experimental validation of potency, absorption, distribution, metabolism, and excretion (ADME) and permeability properties.

Browse report at: https://www.psmarketresearch.com/market-analysis/rms-therapeutics-pipeline-analysis

Some of the key players involved in the development of RMS therapeutics include F. Hoffmann-La Roche Ltd., Epizyme Inc. and Novartis AG.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.